Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,144,000 | 769,000 | 862,800 | 1,183,200 | 1,179,100 |
| Marketable Securities | 500,500 | 446,300 | 604,000 | 219,400 | 337,800 |
| Receivables | 836,900 | 699,100 | 664,900 | 602,800 | 599,100 |
| Inventories | 1,168,200 | 875,500 | 726,700 | 802,300 | 640,900 |
| Other current assets | 239,300 | 195,900 | 237,100 | 208,200 | 168,000 |
| TOTAL | $4,035,700 | $3,095,800 | $3,180,700 | $3,091,000 | $2,984,000 |
| Non-Current Assets | |||||
| PPE Net | 1,749,400 | 1,632,800 | 1,546,600 | 1,395,200 | 1,060,300 |
| Investments And Advances | 583,900 | 1,239,000 | 1,834,200 | 801,600 | 585,500 |
| Intangibles | 1,681,900 | 1,449,500 | 1,491,500 | 1,504,600 | 1,504,200 |
| Other Non-Current Assets | 1,312,300 | 875,400 | 449,600 | 444,700 | 354,100 |
| TOTAL | $5,327,500 | $5,196,700 | $5,321,900 | $4,146,100 | $3,504,100 |
| Total Assets | $9,363,200 | $8,292,500 | $8,502,600 | $7,237,100 | $6,488,100 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 201,400 | 201,900 | 204,500 | 196,500 | 180,400 |
| Accrued Expenses | 969,100 | 795,000 | 802,300 | 670,200 | 696,500 |
| TOTAL | $1,195,400 | $1,022,400 | $1,032,300 | $893,900 | $902,400 |
| Non-Current Liabilities | |||||
| Long Term Debt | 597,000 | 596,300 | 595,700 | 595,000 | 594,400 |
| Other Non-Current Liabilities | 854,400 | 867,100 | 1,038,700 | 1,173,900 | 843,000 |
| TOTAL | $1,448,400 | $1,463,400 | $1,634,400 | $1,768,900 | $1,437,400 |
| Total Liabilities | $2,643,800 | $2,485,800 | $2,666,700 | $2,662,800 | $2,339,800 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 601,300 | 608,313 | 623,207 | 624,519 | 627,368 |
| Common Shares | 650,500 | 646,300 | 642,000 | 636,400 | 218,100 |
| Retained earnings | 8,992,400 | 7,590,000 | 6,068,100 | 4,565,000 | 3,741,600 |
| Other shareholders' equity | -172,900 | -254,900 | -157,600 | -161,200 | -155,700 |
| TOTAL | $6,719,400 | $5,806,700 | $5,835,900 | $4,574,300 | $4,148,300 |
| Total Liabilities And Equity | $9,363,200 | $8,292,500 | $8,502,600 | $7,237,100 | $6,488,100 |